First contraceptive authorised for self-injection

Sayana Press (medroxyprogesterone acetate) can now be self-administered by patients where prescribers consider this to be appropriate. Follow-up should be provided in line with local guidelines.

Sayana Press (medroxyprogesterone acetate) is the only depot contraceptive that is administered subcutaneously.
Sayana Press (medroxyprogesterone acetate) is the only depot contraceptive that is administered subcutaneously.

The depot contraceptive, which launched in 2013, is licensed for long-term contraception in women. It prevents ovulation for at least 13 weeks, but it may take up to one year for fertility to return.

Further information
View Sayana Press drug record
Summary of Product Characteristics
Manufacturer: Pfizer

Patients who are deemed capable of properly self-injecting Sayana Press should be trained in the appropriate technique and supervised during initial administration. The contents of one injector should be administered by subcutaneous injection into the anterior thigh or abdomen. 

Self-administration allows doctors to prescribe up to 12 months’ supply of the contraceptive at a time, potentially increasing patient convenience and reducing the need for return visits to clinics and GP surgeries.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases